Teva Pharmaceutical Industries on Thursday raised its profit outlook for 2018 after reporting a smaller than expected drop in second-quarter net profit, but its shares tumbled eight percent on disappointment over its unchanged revenue outlook. The world’s largest generic drugmaker also reaffirmed that the U.S. Food and Drug Administration is due to make a decision in the middle of September for its migraine treatment fremanezumab, which it had originally hoped to launch in June. “We will be ready to launch immediately after,” CEO Kare Schultz told a conference call. …read more
Source:: Yahoo Finance
